Introduction {#sec1}
============

Calcium (Ca^2+^) is an important second messenger necessary for the excitation-contraction (EC) coupling process in cardiac myocytes ([@ref6]; [@ref7]; [@ref29]), which occurs as a consequence of Ca^2+^ entry to the cytosol due to L-type Ca^2+^ channels that provoke Ca^2+^ release from sarcoplasmic reticulum causing cardiac myocyte contraction. Cardiac relaxation starts when intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) decreases as a result of the activity of sarco/endoplasmic reticulum Ca^2+^ ATPase (SERCA) responsible for the Ca^2+^ reuptake into the sarcoplasmic reticulum and the Na^+^/Ca^2+^ exchanger responsible of the Ca^2+^ extrusion out of cardiomyocytes ([@ref7]; [@ref26]). Ca^2+^ is also required for the activation of signaling pathway that plays minor roles in the healthy heart, for example, those involved in the cardiac remodeling and heart failure ([@ref139]; [@ref26]; [@ref33]; [@ref5]; [@ref22]).

![Scheme summarizing the role of TRP channels in cardiac hypertrophy. Activation of TRP channels can be preceded by stimulation of G-coupled receptors with hypertrophic agonists, by mechanical stress, or pressure overload. The consequent increase of the intracellular Ca^2+^ concentration stimulates different signaling protein, such as PKC, AKT, calcineurin, and NFAT, whose activation promotes TRP channels overexpression and the activation of fetal genes reprograming leading to cardiac hypertrophy.](fphys-10-00159-g001){#fig1}

Among the wide Ca^2+^-permeable channels known in the heart, transient receptor potential (TRP) channels contribute to the Ca^2+^ influx induced by a wide spectrum of physico-chemical stimuli from cellular microenvironments, such as thermal, mechanical stresses, and neurohormonal ([@ref33]). Likewise, a wide variety of vasoactive agent, including endothelin-1, thrombin, ATP, angiotensin-II, or bradykinin, also stimulates TRP ([@ref118]; [@ref3]; [@ref37]; [@ref110]). TRP channels comprise a large Ca^2+^-permeable cation channel superfamily showing a common architecture. They contain six transmembrane domains (TM1--TM6) and the cation-permeable pore region formed by a loop between TM5 and TM6 ([@ref36]). They are divided into six major subgroups based on their specific function and sequence analogies ([@ref86]; [@ref94]; [@ref97]): the canonical channel (TRPC), the vanilloid-related channel (TRPV), and the melastatin-related channel (TRPM) formed by 7, 6, and 8 different channel proteins, respectively ([@ref82]; [@ref121]; [@ref136]); the ankyrin-related channel (TRPA) subfamily containing only one protein; the mucolipin-related channel (TRPML) formed by three proteins; and polycystin-related channel (TRPP) constituted by three members also known as polycystic kidney disease protein (PKD2) ([@ref82]; [@ref121]).

TRP channels display diverse cation selectivity and activation mechanisms ([@ref121]). Most of them are nonselective for cation and are permeable to monovalent and divalent cations, more permeability for Ca^2+^ than Na^+^ (ratio P~Ca~/P~Na~) that ranges from channels selective for monovalent cations, such as TRPM4 and TRPM5 with a ratio P~Ca~/P~Na~ \< 0.05, to highly Ca^2+^ selective channels, as TRPV5 and TRPV6, which exhibit a ratio P~Ca~/P~Na~ close to 100 ([@ref139]). TRPM6 and TRPM7 are also permeable to Mg^2+^, Ca^2+^, Na^+^, Zn^2+^, and other metals \[for an extensive review see [@ref33]\]. Most of TRP channels lack the typical voltage sensor; therefore, they are not gated by voltage ([@ref102]; [@ref4]; [@ref56]) but they can be modulated by a different chemical and physical stimuli, including temperature fluctuations and mechanical stretch ([@ref54]; [@ref85]; [@ref135]), extracellular and intracellular ions (including H^+^, Ca^2+^, and Mg^2+^) ([@ref71]; [@ref57]; [@ref72]), intracellular ligands \[as diacylglycerol ([@ref95]), phosphoinositide-4,5-bisphosphate (PIP2) ([@ref92])\], and various exogenous natural and synthetic ligands ([@ref122]; [@ref48]).

TRP channels have been suggested as regulators of local micro domains signaling pathway related with changes in the \[Ca^2+^\]~i~ or by the interplay with Ca^2+^-dependent regulatory proteins. Actually, they contribute to Ca^2+^ homeostasis by directly conducting Ca^2+^ or indirectly *via* membrane depolarization and modulation of voltage-gated Ca^2+^ channels ([@ref86]; [@ref94]; [@ref34]; [@ref100]). Hence, during the last two decades, TRPs have been suggested as intermediaries of diverse physiological and pathophysiological cardiovascular processes ([@ref52], [@ref53]; [@ref28]; [@ref115]; [@ref139]).

Expression of TRP Channels in Cardiac Cells {#sec2}
===========================================

RT-PCR, western blot, immunostaining, and functional current recordings demonstrated that TRPs are expressed ubiquitously in cardiac myocytes and fibroblasts of different species ([@ref106]; [@ref139]). In the case of TRPC channel, the seven members TRPC1--7 are expressed in the majority of the cell types in heart ([@ref26]; [@ref33]). Consistently, all TRPCs, except TRPC5, were detected in the sinoatrial node ([@ref60]). Interestingly, significant overexpression of TRPC1/C3/C4/C5 or TRPC6 was detected in patients with heart failure as compared to nonfailing heart ([@ref12]; [@ref83]). Interestingly, these TRPC channels show distinct profiles of expression in the ventricles of patients with heart failure as it happens in murine models of univentricular pressure overload ([@ref83]). As in other cell types, TRPC channels are implicated in signal transduction in cardiac myocytes ([@ref32]; [@ref26]; [@ref33]). TRPC family requires the phospholipase C (PLC) pathway for activation. TRPC3, TRPC6, and TRPC7 interact directly with diacylglycerol ([@ref134]), while TRPC1, TRPC4, and TRPC5 are activated indirectly through a still unidentified mechanism ([@ref106]; [@ref143]; [@ref44]). Some TRPC channels are activated by intracellular Ca^2+^ store depletion, which stimulates the store-operated Ca^2+^ entry (SOCE) required for diverse cardiac physiopathological process ([@ref93]; [@ref26]). It has been proposed that TRPC1 associates with TRPC4 or TRPC5, thereby forming the store-operated Ca^2+^ channel, while TRPC3, TRPC6, and TRP7 are suggested to form the receptor-operated channel ([@ref62]; [@ref108]; [@ref104]). Others studies demonstrated that long-term stimulation of cardiac myocytes with angiotensin II, phenylephrine, endothelin-1, or aldosterone evoked an exacerbated SOCE elicited by thapsigargin, correlating with an increment in the expression or activation of TRPC1, TRPC4, and/or TRPC5 ([@ref127]; [@ref80]; [@ref13]; [@ref105]). The use of dominant negative mutants confirmed that TRPC4 is sensitive to passive Ca^2+^ store depletion, while TRPC3 and TRPC6 respond to the diacylglycerol stimulus, regardless of store depletion ([@ref80]). Furthermore, upregulation of TRPC3/C4 in adult ventricular cardiomyocytes correlated with the enhanced SOCE and pro-arrhythmic spontaneous Ca^2+^ waves ([@ref23]). Importantly, transient occlusion of coronary artery in rats also enhanced the expression of TRPC1/C3/C4/C5 and TRPC6 either in risk or in remote zone of the infarcted heart ([@ref22]). Finally, TRPC7 activation was proposed to initiate angiotensin-II activation to myocardial apoptosis ([@ref109]).

TRPV channels were also detected in mammalian hearts, especially TRPV1, TRPV2, and TRPV4 ([@ref139]). Most of TRPV channels are sensitive to temperature and ligands, and they participate in sensation of hot temperature and in chemoreception ([@ref123]; [@ref54]). TRPV1 was identified principally in sensory nerves in the cardiovascular system but also in the myocardium ([@ref141]; [@ref35]; [@ref103]). Bradykinin evoked a TRPV1-dependent \[Ca^2+^\]~i~ increase in cardiac neurons, indicating that TRPV1 activation was responsible for stimulation/sensitization by bradykinin of cardiac nociceptors ([@ref131]). An early study demonstrated that after *trpv1* gene deletion, an exacerbated inflammation and cardiac remodeling occurred due to impaired post-ischemic recovery in isolated perfused infarcted heart ([@ref124]). More recently, the overexpression of TRPV2 after myocardial infarction was observed in cardiac tissue of rats ([@ref31]), and TRPV2 downregulation in knockout mice was related to a better recovery after myocardial infarction ([@ref30]), probably because of an attenuated pro-inflammatory response in these mice. Another study also suggested that TRPV2 may play a critical role in stretch-activated Ca^2+^ influx pathway in dystrophic cardiomyopathy, contributing to \[Ca^2+^\]~i~ mishandling ([@ref77]). In the case of TRPV4, it is also highly expressed in the heart and is activated during myocardial ischemia and reperfusion, which induced Ca^2+^ influx with subsequent reactive oxygen species (ROS) release ([@ref280]). Recently, TRPV4 upregulation in cardiomyocytes was also linked with aging in mice ([@ref58]). Indeed, pharmacological inhibition of TRPV4 with HC067047 prevented stress-induced cardiomyocyte death and ischemia and reperfusion-induced cardiac damage in aged mice. These findings might have potential implications in the treatment of elderly populations at increased risk of myocardial infarction.

Regarding the expression of TRPM channels in hearts, it is known that eight isoforms are present in different parts of the heart, and TRPM2/4/7 is expressed specifically in cardiac myocytes ([@ref139]). The analysis of mRNA and/or protein levels showed that levels of TRPM2, TRPM3 and TRPM8 were reduced in left and right ventricle of patients with failing heart ([@ref83]), meanwhile increased expression of TRPM7 was observed in the left ventricle of patients with ventricular tachycardia ([@ref96]). TRPM2 seems essential for cardiac myocyte bioenergetics maintenance ([@ref47]). Its activation protected the heart from ischemia and reperfusion injury by improving mitochondrial dysfunction and reducing ROS levels ([@ref81]). TRPM4 is thought to interfere in cardiac myocyte contraction by its activation of voltage-gated Ca^2+^ channel ([@ref4]). Actually, the exacerbated activity of TRPM4, which is activated by physiological range of Ca^2+^ concentration, was related with arrhythmic changes ([@ref50]). Also, TRPM7 is believed indispensable during the myocardial proliferation in early stages of cardiogenesis, since the deletion of *trpm7* gene, before embryonic day 9 of mice, provoked heart failure and embryonic death ([@ref107]). Nevertheless, the mechanism by which TRPM7 regulates cardiac cell proliferation remains unknown ([@ref290]).

In relation to the expression and function of other TRP channels in heart, TRPA1 was detected in cardiac endothelial cells, vascular smooth muscle, and in cardiac myocytes ([@ref139]), where its activation seems relevant to attenuate ischemia and reperfusion injury ([@ref79]). Furthermore, the presence of TRPP2 has been proven in knockout mice who died before birth as a result of cardiac malformations ([@ref98]). Recently, a study confirmed that TRPP2 was able to regulate autophagy through Ca^2+^ homeostasis in cardiac myocytes ([@ref17]). However, there are only few studies which looked on the role of these channels in the function of cardiac cells.

Role of TRP Channels in the Adverse Cardiac Remodeling {#sec3}
======================================================

Ca^2+^ plays critical role in the adaptation of the heart to environmental demands, leading to cardiac remodeling ([@ref26]; [@ref5]). Physical exercise or pregnancy are reversible stimuli that induce physiologic cardiac hypertrophy to adapt the increase in consumption of nutrients and oxygen, whereas sustained neurohumoral activation, hypertension, or myocardial injury can lead to pathological heart hypertrophy followed by interstitial fibrosis ([@ref99]; [@ref66]; [@ref46]). These events might cause left ventricular dilation and dysfunction, what is known as the adverse cardiac remodeling, which increases the risk of heart failure and malignant arrhythmia ([@ref46]; [@ref120]).

Initial attentions have been given to describe the role of TRP channels in the appearance of cardiac remodeling using different experimental procedures *in vitro* and *in vivo* in animal models ([@ref40]; [@ref27]; [@ref139]). Here, we will focus on the role of TRPCs, TRPVs, and TRPMs role in the adverse cardiac remodeling, since little is known regarding the other subfamilies and their participation in these processes.

TRPs and Cardiac Hypertrophy {#sec4}
----------------------------

Compelling evidence confirmed that the activity and expression of several TRP channels are upregulated in pathological hypertrophy and heart failure as reviewed elsewhere ([@ref127]; [@ref139]; [@ref33]), and as summarized in [Figure 1](#fig1){ref-type="fig"}. Special attention has been given to TRPC's role in cardiac hypertrophy, but the implication of TRPV1, TRPV2, and TRPM4 has been also demonstrated.

### TRPCs and Hypertrophy {#sec5}

The role of TRPCs in the pathological cardiac hypertrophy has been extensively studied in isolated neonatal and adult cardiac myocytes and in different animal model of cardiac hypertrophy ([@ref87]; [@ref127]; [@ref27]; [@ref132]). Ca^2+^ entry through TRPCs is considered essential to activate signaling pathways involving PKC, calmodulin-kinase, and calcineurin/NFAT, which promotes cardiac hypertrophy by the re-expression of the fetal gene program ([@ref45]; [@ref84]; [@ref27]). Independent reports demonstrated that stimulation of neonatal rat cardiac myocytes with hypertrophic agonists such as ATP, endothelin-1, phenylephrine, or angiotensin-II, increased cells size, correlating with the upregulation and activation of TRPC1 ([@ref91]), TRPC3 ([@ref9]), TRPC5 ([@ref117]), and TRPC7 ([@ref109]). Using animal models of pressure overload-induced heart hypertrophy, different studies demonstrated that TRPC1 ([@ref91]), TRPC3 ([@ref12]; [@ref9]), and TRPC6 ([@ref69]) are upregulated in heart. Conversely, the overexpression of TRPC3 in transgenic mice increased cardiac hypertrophy through calcineurin/NFAT activation when mice were subjected to angiotensin-II and phenylephrine treatment or pressure overload ([@ref84]). Similarly, the overexpression of TRPC6 in transgenic mice leaded to the development of cardiac hypertrophy and heart failure ([@ref69]). In contrast, the use of cardiomyocyte-specific dominant-negative mutants in transgenic mice for TRPC3 and TRPC6 or for TRPC4 reduced cardiac hypertrophic responses following either the infusion of neuroendocrine agonists or pressure overload stimulation through calcineurin/NFAT ([@ref129]). Moreover, *trpc1* gene deletion in mice attenuated pressure overload-induced hypertrophy by the alteration of calcineurin/NFAT and Akt signaling pathway ([@ref112]). Intriguingly and in contrast to other studies mentioned here, a previous study reported that TRPC3/TRPC6 double knockout mice did not develop pressure-overload induced hypertrophy; however, *trpc3* or *trpc6* gene's deletion did not protect the heart from hypertrophy or dysfunction due to pressure overload, suggesting the need of both channels to promote the deleterious hypertrophic response ([@ref111]). This finding worth further investigation and confirmation in other model of pathological cardiac hypertrophy.

### TRPVs and Hypertrophy {#sec6}

Most studies focused on TRPV1 and TRPV2 role in hypertrophy and the adverse cardiac remodeling. An early study revealed that TRPV1 knockout mice showed a reduced increase in heart's weight as compared to wild-type mice, and they were partially protected from pressure-overload induced cardiac hypertrophy ([@ref10]). A recent study demonstrated that TRPV1's expression is increased in hypertrophied heart of mice evoked by transverse aorta constriction (TAC) ([@ref15]). However, *Trpv1* gene's deletion was associated with excessive inflammation, exaggerated cardiac hypertrophy, and abnormal cardiac function after TAC, suggesting a protective role of TRPV1 ([@ref148]). This study proposed that TRPV1, highly expressed in sensory nerves, might be involved in the regulation of cardiovascular function due to its anti-inflammatory effects *via* calcitonin gene-related peptide. Conversely, a previous study revealed that pharmacological activation of TRPV1 with SA13353 prevents the increase of cardiomyocyte size evoked by endothelin-1 ([@ref146]). SA13353 also attenuated and reduced cold stress-induced hypertrophy and decreased the fractional shortening among others functional cardiac and cellular parameters ([@ref146]). In contrast, another study showed that TRPV1 activation with capsaicin can antagonize high-salt diet-mediated cardiac hypertrophy, by ameliorating the mitochondrial complex I oxidative phosphorylation and suggesting that TRPV1-mediated amendment of mitochondrial dysfunction may represent a novel target for the management of early cardiac dysfunction ([@ref70]). Therefore, the role of TRPV1 in the molecular mechanism underlying pathological cardiac hypertrophy still remains unclear.

TRPV2 is also significantly upregulated in wild-type mice subjected to TAC, whereas the absence of functional TRPV2 reduces significantly the left ventricular hypertrophy after TAC, suggesting a role of TRPV2 in the development of cardiomyocyte hypertrophy because of an increased afterload ([@ref67]). In this way, the overexpression of TRPV2 was also associated with enlarged hearts in patients with dilated cardiomyopathy ([@ref55]). TRPV3 is also overexpressed in angiotensin-II-induced cardiomyocyte hypertrophy, which aggravated cardiac hypertrophy through calcineurin/NFATc3 signaling pathway activation ([@ref142]).

### TRPMs and Hypertrophy {#sec7}

In the case of TRPMs, different studies focused especially on TRPM4 role in hypertrophy, while little is known regarding other TRPM channels. TRPM4 is thought to fine-tune the amount of Ca^2+^ influx into cardiomyocytes via store-operated Ca^2+^ channels after chronic angiotensin-II stimulation, through a mechanism involving calcineurin--NFAT activation ([@ref64]). TRPM4 upregulation was observed in hypertrophied ventricular cardiomyocytes freshly isolated from well-established genetic model of spontaneously hypertensive rats when compared to control, the Wistar Kyoto rats ([@ref41]). Interestingly, selective removal of TRPM4 from the heart resulted in an increased hypertrophic growth after chronic mice treatment with angiotensin-II as compared to wild type mice ([@ref64]), suggesting a protective role of TRPM4. Recently, a study confirmed the beneficial role of TRPM4 in hard training-induced physiological hypertrophy because TRPM4 knockout mice developed a pathological cardiac hypertrophy when they were subjected to endurance training ([@ref20]). The deletion of the *Trpm4* gene in 12-week-old mice was linked with moderate cardiac hypertrophy as well as ventricular dilation, increased cellular density, and reduced left ventricular cardiomyocytes size, suggesting that TRPM4 might act as a negative regulator of cardiomyocytes proliferation during prenatal development ([@ref20]).

Role of TRPs in Interstitial Fibrosis {#sec8}
-------------------------------------

Cardiac fibroblasts represent ∼75% of all cardiac cells, although they represent about ∼10--15% of total cardiac cell volume due to their small size. However, the activation of cardiac fibroblasts plays a crucial role in cardiac pathology. Cardiac fibrosis is caused by an excessive extracellular matrix proteins produced by myofibroblasts, the differentiated phenotype of fibroblasts under stress situations ([@ref140]), where the Ca^2+^ signaling is essential for transcriptional control regulation and myocardial fibrosis ([@ref101]), as illustrated in [Figure 2](#fig2){ref-type="fig"}. The role of TRP channels in cardiac fibroblasts activation, proliferation, and differentiation has been extensively investigated ([@ref24]; [@ref140]; [@ref14]). However, unlike in cardiac myocytes, TRPs-activated Ca^2+^ signaling mechanisms are not fully understood in fibroblasts.

![Scheme summarizing the role of TRP channels in cardiac fibrosis. In pathological conditions, different kind of stress stimulates Ca^2+^ entry in cardiac myocyte through TRP channels and other signaling pathway as RhoA dependent on reactive oxygen species (ROS) production, which lead to profibrotic gene's expression. Profibrotic agonists and other stimuli activate cardiac fibroblast (green) leading to their proliferation and differentiation. The intracellular Ca^2+^ concentration increase through TRP channels promotes the expression of pro-fibrotic agonist (TGF-β1), α-SMA, collagen, and different isoforms of TRP channels, leading to exacerbated extracellular matrix synthesis and fibrosis.](fphys-10-00159-g002){#fig2}

### TRPCs and Fibrosis {#sec9}

TRPC1, TRPC3, and TRPC6 are considered the main TRPCs implicated in cardiac fibrosis, but most studies focused on TRPC3's role in cardiac fibrosis, as reviewed recently ([@ref90]). A role of background Ca^2+^ entry through TRPC1 and TRPC4 was associated with fibrosis in double knockout mice subjected to pressure overload ([@ref13]). In mechanically stressed hearts, TRPC3 activation triggered an aberrant increase of ROS production, leading to RhoA activation in both cardiac myocytes and fibroblasts, resulting in interstitial fibrosis ([@ref65]). Actually, *trpc*3 gene deletion suppressed cardiac fibrosis in response to pressure overload or to angiotensin-II infusion ([@ref21]; [@ref65]; [@ref89]). TRPC3 blockade with Pyr3 also inhibited angiotensin-II-induced Ca^2+^ entry, proliferation, and differentiation of fibroblasts isolated from left atrial of electrically maintained atrial fibrillation in a dog model ([@ref43]). Recently, chronic treatment of rat models of pressure overload with GSK503A, proposed to inhibit both TRPC3 and TRPC6, showed no interstitial cardiac fibrosis ([@ref111]), suggesting that TRPC3 and TRPC6 are needed for the fibrosis appearance. TRPC6 has been supposed as a regulator of myofibroblast differentiation, since its silencing in human cardiac fibroblasts attenuated the upregulation of α-SMA, a marker of myofibroblast transformation, induced by TGF-β1, a pro-fibrotic agonist ([@ref63]). Conversely, the loss of TRPC6 in knockout mice prevented TGF-β1-mediated myofibroblast transformation. In addition, TRPC6 overexpression using adenovirus promoted fibroblast conversion to myofibroblast, a hallmark of fibrosis ([@ref19]). In contrast to this finding, an early report proposed that silencing of TRPC6 enhanced myofibroblast formation ([@ref88]), which questions whether TRPC6 is relevant for cardiac fibrosis.

### TRPVs and Fibrosis {#sec10}

TRPV channels seem also critical for cardiac fibroblast differentiation to myofibroblasts. It was shown that the ablation of TRPV1 markedly enhanced the fibrosis due to myocardial infarction, by the stimulation of the TGF-β1 and Smad2 signaling pathway ([@ref51]). In contrast, the administration of a TRPV1 antagonist in TAC mice protected the heart from the fibrotic process ([@ref49]). Conversely, in a pressure-overload mice model, it demonstrated a reduction of hypertrophy and fibrosis-mediated TRPV1 channel activation by capsaicin ([@ref125]). Capsaicin blunted pressure overload--induced upregulation of TGF-β1 and Smad2/3 phosphorylation. It also reduced angiotensin-II-induced proliferation of cardiac fibroblast isolated from wild-type but not from TRPV1-knockout mice ([@ref125]). Recently, the overexpression of TRPV1 in transgenic mice-attenuated isoproterenol-induced myocardial fibrosis *in vitro* and *in vivo* in primary cultured cardiac fibroblasts ([@ref126]).

Other reports suggested that TRPV2, TRPV3, and TRPV4 channels also participate in cardiac fibrosis. TRPV2 functional deletion was associated with a decreased development of fibrosis associated with aging ([@ref59]), while TRPV2 upregulation was associated with enlarged hearts, increased fibrosis, and myocardial structural defects in patients with dilated cardiomyopathy ([@ref55]). Furthermore, TRPV3 activation intensified cardiac fibrosis, stimulating cardiac fibroblast proliferation in the pressure-overloaded rat hearts ([@ref76]). TRPV4 seems also necessary for cardiac fibroblasts differentiation to myofibroblasts, since AB159908, a TRPV4 antagonist, as well as TRPV4 siRNA inhibited TGF-β1-induced fibroblasts differentiation ([@ref1]). Actually, TRPV4-knockout mice presented decreased fibrosis after myocardial infarction ([@ref2]).

### TRPMs and Fibrosis {#sec11}

Several reports made special attention to the abnormal expression of TRPM7 and the development of cardiac fibrosis; however, little is known regarding other TRPM channels ([@ref133]). Recently, higher amount of mRNA and protein levels of TRPM6 in addition to significant increase in markers of myocardial fibrosis as TGF-β1, collagen I and III, were detected in atrial fibrillation patients, suggesting possible contribution of TRPM6 to atrial fibrosis ([@ref145]).

Experimental strategies treating human or animal cardiac fibroblasts with pro-fibrotic agonists or with hormones as angiotensin-II increased significantly the expression of TRPM7. In fact, TGF-β1 addition to human atrial fibroblasts upregulated the expression of TRPM7; meanwhile, TRPM7 silencing inhibited fibroblasts proliferation, differentiation, and collagen production induced by TGF-β1 ([@ref24]). Angiotensin-II also stimulated TRPM7 resulting in an increased expression of α-SMA and fibronectin protein ([@ref137]). Moreover, rat cardiac fibroblasts incubated with angiotensin-II increased levels of protein expression of TRPM7, collagens I and III, which promoted fibrosis ([@ref150]). In contrast, the downregulation of TRPM7 decreased its related current density and inhibited angiotensin-II mediated cardiac fibroblasts proliferation, differentiation, and collagen synthesis ([@ref73]). Moreover, in rats with sick sinus syndrome, TRPM7 regulated angiotensin II-induced cardiac fibroblasts proliferation and collagen synthesis of sinoatrial node, involving Smad signaling pathway ([@ref149]). Recently, a role of TRPM7 was reported in miRNA-135a inhibition of isoproterenol-induced cardiac fibrosis ([@ref130]) and in fibrosis evoked by H~2~O~2~ and hypoxia ([@ref42]; [@ref78]). Therefore, TRPM7 stand out as an interesting possible target to attenuate pathological cardiac fibrosis.

TRPs and Conduction Disorders {#sec12}
-----------------------------

Atrial fibrillation (AF) is the most sustained clinical arrhythmia, which occurs due to structural remodeling, involving prominent fibrotic changes ([@ref138]). TRP channels do not influence the excitability of heart's pacemaker but apparently their upregulation mediate the arrhythmogenesis and the progression of electrical remodeling of the diseased heart ([@ref139]). Special advances have been made by studying the role of TRPM4, TRPC3, and TRPM7 in conduction disorders in the heart.

TRPM4 contribution to cardiac conduction as well as the development of arrhythmias has been demonstrated using different approaches, such as channel inhibition with 9-phenantrol, a blocker for TRPM4 ([@ref38]), using TRPM4-deficient mouse models, and by the identification of TRPM4 mutants detected in a variety of inherited human cardiac arrhythmias ([@ref33]). A pro-arrhythmic role of TRPM4 and its participation in membrane potential depolarization likely explain the triggering of spontaneous beating and the increase of action potential duration described in the hypertrophied heart ([@ref20]). *In vitro* experiments showed that 9-phenanthrol decreased Ca^2+^ oscillations in atrial HL-1 mouse cardiac myocytes, thought to play a critical role in arrhythmias ([@ref11]). TRPM4 inhibition with 9-phenanthrol also mimicked the reduction of action potential duration evoked by TRPM4 deletion in atrial cells ([@ref113]) and reverted the early after-depolarization involved in cardiac arrhythmias observed after a process of hypoxia and re-oxygenation ([@ref114]). Recently, it was shown that physiological range of \[Ca^2+^\]~i~ could activate TRPM4, and its upregulation altered action potential characteristics in HL-1 cells treated with angiotensin-II, which increased the arrhythmic propensity of cardiac tissue in pathological situation ([@ref50]). Interestingly, *trpm4* gene mutations were linked to progressive familial heart block type 1 ([@ref68]; [@ref18]), isolated cardiac conduction disease ([@ref75]), atrio-ventricular block ([@ref116]; [@ref119]), right bundle branch block ([@ref116]), Brugada syndrome ([@ref74]; [@ref39]), and recently to either complete heart block or idiopathic ventricular fibrillation ([@ref8]).

Additional indications suggested that TRPM7 and TRPC3 might also mediate the pathogenesis of AF. In atrial fibroblasts from AF patients, TRPM7 is notably upregulated ([@ref24]; [@ref144]) and was suggested to play a pivotal role in AF due to fibrogenesis in the atrium since fibrosis is the main factor for AF. TRPM7 knockdown suppressed endogenous TRPM7 currents, decreased Ca^2+^ influx in atrial fibroblasts, and inhibited TGF-β1-induced fibroblast proliferation, differentiation, and collagen production ([@ref24]). TRPC3 is also significantly upregulated in the atria of AF patients ([@ref147]). In fibroblasts freshly isolated from left atrial of dogs undergoing AF, by sustained atrial tachypacing, it was observed a significantly increase in TRPC3 protein expression, currents, ERK phosphorylation, and extracellular matrix gene expression ([@ref43]). Further evidence for a role of TRPC3 has been demonstrated in experiments using TRPC3 knockout mice, in which the effect of angiotensin-II addition to pacing-induced AF mice was significantly reduced compared to wild-type mice ([@ref61]). Interestingly, a recent study examined the expression of different TRPs in leukocytes of patients with nonvalvular AF ([@ref25]). They observed marked increase in gene expression of TRPC1-C7, TRPV1-V6, TRPM1-M8, TRPML1-ML3, TRPA1, and TRPP2. A possible correlation between these leukocytes genes' expression and those examined from the atrium will be of major interest. Therefore, further investigations are undoubtedly needed for understanding the role of all these TRP channels in AF.

Conclusions and Perspectives {#sec13}
============================

A growing body of evidence has demonstrated that, by controlling Ca^2+^ homeostasis, different TRP isoforms are critically involved in pathological cardiac remodeling and heart failure. However, molecular mechanisms which trigger the transition of the heart from adaptation to maladaptation by these channels are still unknown. In the last two decades, the use of genetically modified animal and mice models of cardiac disease provided valuable information about TRPs implication in cardiac remodeling. Nevertheless, substantial work is still required to understand why many TRPs from different subfamilies are activated by similar pro-hypertrophic or pro-fibrotic stimuli, and whether they associate or interact between them to activate signaling pathway involved in hypertrophy, fibrosis, or conduction disorders. Unfortunately, the wide range of agonists and antagonists used to modulate TRPs failed to determine which TRPs might be the right target(s) to characterize and consider as therapeutic tools. More specific inhibitors/activators of TRPs are eagerly awaited to shed a light on the complex mechanism of cardiac diseases associated with remodeling. Of hope, the increasing amount of available information related to TRP-drug interaction sites and gating processes of TRP channels is expected to facilitate the development of novel therapeutic concepts by pharmaceutical companies. Overall, and in the light of the reported studies, TRP channels are still considered promising therapeutic targets to regulate pathological cardiac plasticity.
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